Nitrosourea
Appearance
(Redirected from Nitrosoureas)
| |||
Names | |||
---|---|---|---|
IUPAC name
Nitrosourea
| |||
Identifiers | |||
3D model (JSmol)
|
|||
ChemSpider | |||
PubChem CID
|
|||
UNII | |||
CompTox Dashboard (EPA)
|
|||
| |||
| |||
Properties | |||
CH3N3O2 | |||
Molar mass | 89.054 g·mol−1 | ||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Nitrosourea is both the name of a molecule, and a class of compounds that include a nitroso (R-NO) group and a urea.
Examples
[edit]Examples include:
- Arabinopyranosyl-N-methyl-N-nitrosourea (Aranose)
- Carmustine (BCNU, BiCNU)
- Chlorozotocin
- Ethylnitrosourea (ENU)
- Fotemustine
- Lomustine (CCNU)
- Nimustine
- N-Nitroso-N-methylurea (NMU)
- Ranimustine (MCNU)
- Semustine
- Streptozocin (Streptozotocin)
Nitrosourea compounds are DNA alkylating agents and are often used in chemotherapy.[1] They are lipophilic and thus can cross the blood–brain barrier, making them useful in the treatment of brain tumors such as glioblastoma multiforme.[2]
Side effects
[edit]Some nitrosoureas (e.g. lomustine) have been associated with the development of interstitial lung disease.[3]
References
[edit]- ^ "Antineop". Archived from the original on 2009-03-07. Retrieved 2009-01-24.
- ^ Takimoto CH, Calvo E. "Principles of oncologic pharmacotherapy". in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer management: a multidisciplinary approach. 11 ed. 2008.
- ^ Tucci E, Verdiani P, Di Carlo S, Sforza V (1986). "Lomustine (CCNU)-induced pulmonary fibrosis". Tumori. 72 (1): 95–8. doi:10.1177/030089168607200114. PMID 3952821. S2CID 33327504.
External links
[edit]- Nitrosourea+Compounds at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Diseases Database (DDB): 9052